Rating: Downgrade / Wait - The Space Force contract is real, but it doesn't justify the valuation. The $3B ATM filing is the signal that demands attention. Don't chase this move.
What more do the bulls need from Rocket Lab?
The company just announced a $90 million Space Force contract to build two geostationary satellites with space-domain awareness payloads. The stock jumped overnight. The narrative machine revved up.
Here's what the narrative machine is ignoring: Rocket Lab trades at roughly $77 billion in market capitalization. It generated $602 million in annual revenue last year. That's a revenue multiple north of 127x. And the company - as of Q1 2026 - is still not profitable on a GAAP basis.
The $90 million deal is a rounding error at this valuation. It represents 15% of annual revenue. At a $77 billion market cap, it's 0.12%. The market already knew Rocket Lab was winning Space Force work. In December 2025, the company landed an $816 million contract for 18 missile-tracking satellites. The $90 million Heimdall contract is incremental, not transformative.
The real story wasn't the deal. It was the filing Rocket Lab made the same day.
The ATM elephant in the room
On May 21, Rocket Lab registered up to $3 billion of common stock in an at-the-market (ATM) offering program. An ATM lets a company sell shares continuously into the public market at prevailing prices - no fixed offering date, no minimum price floor. It's a flexible capital-raising tool, but it's also a dilution overhang. Existing shareholders should understand that up to $3 billion in new shares could enter the market, thinning their ownership.
Shares dropped 4% to 7% on the announcement before the Space Force contract pushed them back up overnight. The market blinked at dilution, then looked the other way. That's the behavior I'd expect from a stock riding narrative momentum, not one being valued on fundamental discipline.
At a $77 billion market cap with 578.75 million shares outstanding, even a partial exercise of the ATM program would add meaningful dilution. If Rocket Lab sells a full $3 billion at current prices, that's roughly 240 million new shares - a 41% increase in the share count. The company hasn't committed to selling anything yet, but the registration itself signals that management is preparing for heavy capital needs, likely tied to Neutron development.
Growth is real. The multiple is not.
Let me be clear about what Rocket Lab is doing right. Q1 2026 revenue hit $200.3 million - a 63.5% year-over-year jump and the first time the company has topped $200 million in a quarter. The backlog sits at $2.2 billion, up sharply from a year ago. The Space Systems segment, which builds satellites and operates the Photon spacecraft in orbit, posted non-GAAP gross margins above 44%, and the company is projecting positive free cash flow in 2026 and GAAP profitability by 2027.
This is a company that has moved from concept to execution. The growth trajectory is impressive. The margins are expanding.
But here's where the GARP lens matters: growth alone doesn't justify a 127x revenue multiple. Even the most dominant technology companies in their breakout years don't command multiples this far from earnings reality without a proven profit model. Rocket Lab is still burning cash. Neutron - the heavy-lift rocket that would put Rocket Lab in SpaceX's league - hasn't flown yet. It was delayed to late 2026 after a Stage 1 tank test failure in January.
Neutron is the optionality, not the foundation. And options don't belong in the base case.
What would change the equation?
I'm not arguing Rocket Lab isn't a good company. The execution on Electron, the Photon platform, and the growing defense contract pipeline is real. But a good company isn't automatically a good investment at any price.
The setup for a lower-risk entry would require: either Neutron achieving its first successful orbital flight and demonstrating that the heavy-lift business model is viable, or the stock pulling back to a valuation that reflects current earnings power rather than hypothetical future dominance.
Until then, the math doesn't work. A $77 billion market cap for a $602 million revenue company that hasn't turned a profit yet, while registering $3 billion in potential share dilution - this is pre-IPO pricing for a public company. The market has arguably baked in a world where Neutron succeeds flawlessly and Rocket Lab captures a massive share of the national security launch market.
That outcome is possible. But it's priced in. The risk/reward here doesn't tilt in your favor.
The move
I'm not in a hurry here. The Space Force contract is a nice win, but it doesn't change the fundamental equation. If you own RKLB, I wouldn't add to the position. If you're watching, wait for a deeper pullback or for Neutron to actually fly before committing capital. The growth story is compelling, but growth stories at 127x revenue with an unproven second rocket and a $3 billion dilution overhang are where conviction meets caution.
I would reassess my view if Neutron achieves its first successful launch, or if the stock corrects to a valuation that provides actual margin of safety. Until then, don't let the headline chase you in.